0000950159-19-000129.txt : 20190828 0000950159-19-000129.hdr.sgml : 20190828 20190828060311 ACCESSION NUMBER: 0000950159-19-000129 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20190828 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20190828 DATE AS OF CHANGE: 20190828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cigna Corp CENTRAL INDEX KEY: 0001739940 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 824991898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38769 FILM NUMBER: 191059071 BUSINESS ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 BUSINESS PHONE: 8602266000 MAIL ADDRESS: STREET 1: 900 COTTAGE GROVE ROAD CITY: BLOOMFIELD STATE: CT ZIP: 06002 FORMER COMPANY: FORMER CONFORMED NAME: Halfmoon Parent, Inc. DATE OF NAME CHANGE: 20180508 8-K 1 cigna8k.htm CIGNA CORPORATION FORM 8-K
 
SECURITIES AND EXCHANGE COMMISSION
 

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 28, 2019

Cigna Corporation
 (Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
333-224960
(Commission File Number)
82-4991898
 (IRS Employer
Identification No.)


900 Cottage Grove Road
BloomfieldConnecticut 06002
(Address of principal executive offices)  (Zip Code)

Registrant’s telephone number, including area code:

(860226-6000

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.01
CI
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Central Index Key: 0001739940


Item 7.01    Regulation FD Disclosure.
Cigna Corporation (“Cigna”) officials expect to participate in meetings with investors and analysts over the next several weeks.  During these meetings, Cigna officials expect to reaffirm projected full year 2019 consolidated adjusted income from operations, which remains in the range of $6.34 billion to $6.46 billion.
Cigna discussed its full year 2019 outlook in its press release dated August 1, 2019 and during the related investor conference call.  The press release and the conference call transcript are available under Quarterly Reports and SEC Filings in the Investor Relations section of the Company’s website located at www.cigna.com/aboutcigna/investors.
Adjusted income (loss) from operations is defined as shareholders’ net income (loss) excluding the following after-tax adjustments:  net realized investment results, amortization of acquired intangible assets, special items, and earnings contributions from transitioning pharmacy benefit management clients, Anthem Inc. and Coventry Health Care, Inc.  Adjusted income (loss) from operations is a measure of profitability used by Cigna’s management because it presents the underlying results of operations of Cigna’s businesses and permits analysis of trends in underlying revenue, expenses and shareholders’ net income.  This consolidated measure is not determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income.  Management is not able to provide a reconciliation to shareholders’ net income (loss) on a forward-looking basis because we are unable to predict certain components thereof including (i) future net realized investment results, and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond our control. As such, any associated estimate and its impact on shareholders’ net income could vary materially.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such a filing.
CAUTIONARY STATEMENT FOR PURPOSES OF THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This Current Report on Form 8-K (the “Report”), and oral statements made with respect to information contained in this Report, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are based on Cigna's current expectations and projections about future trends, events and uncertainties.  These statements are not historical facts.  Forward-looking statements may include, among others, statements relating to our projected full year 2019 consolidated adjusted income from operations as reflected in Item 7.01 of this Report, as well as statements made in our press release dated August 1, 2019 and related investor conference call concerning our projected adjusted income (loss) from operations outlook for 2019, on a consolidated, per share and segment basis; projected adjusted revenue outlook for 2019; projected global medical customer growth over year end 2018; projected client retention; projected growth beyond 2019; statements concerning our long-term projected adjusted income (loss) from operations outlook; projected medical care and SG&A expense ratios and medical cost trends; projected adjusted pharmacy scripts; our projected consolidated adjusted tax rate; projected debt to capitalization ratio; projected cash flow from operations; future financial or operating performance, including our ability to deliver affordable, personalized and innovative solutions for our customers and clients; future growth, business strategy, strategic or operational initiatives; economic, regulatory or competitive environments, particularly with respect to the pace and extent of change in these areas; financing or capital deployment plans and amounts available for future deployment; our prospects for growth in the coming years; the merger (the “Merger”) with Express Scripts Holding Company (“Express Scripts”) and other statements regarding Cigna's future beliefs, expectations, plans, intentions, financial condition or performance. You may identify forward-looking statements by the use of words such as “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.



Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical and pharmacy costs and price effectively; our ability to adapt to changes or trends in an evolving and rapidly changing industry; our ability to effectively differentiate our products and services from those of our competitors and maintain or increase market share; our ability to develop and maintain good relationships with physicians, hospitals, other health care providers and pharmaceutical manufacturers; changes in drug pricing; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits (including anticipated synergies) of such transactions in full or within the anticipated time frame, including with respect to the Merger, as well as our ability to integrate operations, resources and systems; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and/or guaranty fund assessments; uncertainties surrounding participation in government-sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; the impact of our debt service obligations on the availability of funds for other business purposes; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; as well as more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available on the Investor Relations section of www.cigna.com. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Cigna undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.




SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
Cigna Corporation
     
     
Date:  August 28, 2019
By:
/s/ Eric P. Palmer
   
Eric P. Palmer
   
Executive Vice President and
   
Chief Financial Officer
EX-101.SCH 2 ci-20190828.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ci-20190828_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company EX-101.PRE 4 ci-20190828_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 cigna8k_htm.xml IDEA: XBRL DOCUMENT 0001739940 2019-08-28 2019-08-28 false 8-K 2019-08-28 Cigna Corporation DE 333-224960 82-4991898 900 Cottage Grove Road Bloomfield CT 06002 860 226-6000 false false false false Common Stock, Par Value $0.01 CI NYSE false 0001739940 XML 6 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document and Entity Information
Aug. 28, 2019
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 28, 2019
Entity Registrant Name Cigna Corporation
Entity Incorporation, State or Country Code DE
Entity File Number 333-224960
Entity Tax Identification Number 82-4991898
Entity Address, Address Line One 900 Cottage Grove Road
Entity Address, City or Town Bloomfield
Entity Address, State or Province CT
Entity Address, Postal Zip Code 06002
City Area Code 860
Local Phone Number 226-6000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001739940
Title of 12(b) Security Common Stock, Par Value $0.01
Trading Symbol CI
Security Exchange Name NYSE
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://cigna.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cigna8k.htm ci-20190828.xsd ci-20190828_lab.xml ci-20190828_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cigna8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "cigna8k.htm" ] }, "labelLink": { "local": [ "ci-20190828_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ci-20190828_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ci-20190828.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 1, "total": 1 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ci", "nsuri": "http://cigna.com/20190828", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "c20190828to20190828", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://cigna.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "cigna8k.htm", "contextRef": "c20190828to20190828", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://cigna.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0000950159-19-000129-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950159-19-000129-xbrl.zip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end